Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3172
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides.

    To find out more about Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
AB Science
Abbott
Acceleron Pharma
Active Biotech
Adherex
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambrilia Biopharma
Amgen
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Anza Therapeutics
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardana
Ardea Biosciences
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Baxter International
Bayer
Betapharma
BioAlliance Pharma
Biocompatibles
Biogen Idec
Biokine Therapeutics
Bionovo
BioNumerik
BioSante
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chiasma
Choongwae
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
CompleGen
Compugen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CritiTech
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
Dongkook Pharm
Dynavax Technologies
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
FasTrack Pharmaceuticals
FibroGen
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IkerChem
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Karyon-CTT
Kiadis
Kirax
Kyowa Hakko Kirin
Labopharm
Lee’s Pharmaceutical
Leo
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
NicOx
Nidus Laboratories
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
POZEN
Pro-Pharmaceuticals
ProMetic Life Sciences
Protagonist
Protgen
Protherics
Q Chip
QLT
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SciClone Pharmaceuticals
Serometrix
Shire
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
SRI International
SuperGen
Supratek Pharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targepeutics
Tau Therapeutics
Taxolog
Telik
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroMed
Wyeth
Xerion
Xigen
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zeria
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
aflibercept
AGS-1C4D4
angiopep+paclitaxel
Angiozyme
apricoxib
ARC-100
ARQ-197
bardoxolone methyl
bevacizumab
bosutinib
brivanib alaninate
brivudine
Cabozantinib
capecitabine
catumaxomab
CBP-501
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
corticorelin acetate
CPI-613
CRLX-101
dalotuzumab
dasatinib
deslorelin
docetaxel
doxifluridine
doxorubicin
E-75
E-7820
emepepimut-S
eniluracil
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
FPI-01
ganitumab
gefitinib
goserelin
GSK-1120212
GV-1001
GVAX
GX-301
Her-2/Neu peptides
histrelin
icotinib hydrochloride
imatinib mesilate
imMucin
IMP-321
interferon gamma
ipilimumab
IPP-204106
irinotecan
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
kahalalide F
KD032
L19-IL2
lanreotide
lapatinib ditosylate
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LipoVIL12
masitinib
MDX-1379
MetXia
MGN-1703
MKC-1
mocetinostat
motexafin gadolinium
nadroparin
NAFB001
netupitant
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
olaparib
OTS-102
ozarelix
P-276-00
paclitaxel
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
plitidepsin
polyclonal antibody stimulator
PX-12
raltitrexed
ramucirumab
regorafenib
Rexin-G
rindopepimut
romidepsin
romurtide
RX-0201
selumetinib
siltuximab
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Survivac
talminogene laherparepvec
tegafur + uracil
tegafur + uracil + leucovorin
temsirolimus
thymalfasin
tigatuzumab
TM-30339
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vapreotide, immediate-release
varlitinib
vismodegib
vitespen
volociximab
VX-001
WX-671
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides.
    To find out more about Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Prostate Cancer. Learn More


Triple Analysis: Lymphoma, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Angiogenesis, Antibodies and Peptides
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides. Learn More


Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More